Welcome to the 9th EAPS Congress Programme Scheduling

Abstract Body

Neonatal neuroprotection strategies are still in development and few therapies have withstood the long transition from pre-clinical to Phase III trials. Therapeutic hypothermia has transformed the landscape of treatment of hypoxic ischemic encephalopathy and remains the only proven intervention to mitigate poor neurodevelopmental outcomes in infants with moderate and severe encephalopathy. However, for mild HIE who were not included in the trials, the fundamental question of how to manage remains problematic. While this topic persisted in yearly panels, commentaries and opinions, no new RCT data have emerged to support or refute treatment. We will summarize new biomarkers to guide patient selections at birth. A standardized protocol that includes neuroimaging and neurodevelopmental follow-up is proposed when providing care for any infant with HIE irrespective of its initial severity and decisions of cooling. Further we investigate community stakeholder perspectives surrounding the science and treatment of mild HIE. Stakeholder engagement and new biomarkers should be compass in designing the next generation of clinical trials for treatment of mild HIE.